Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Director departure
Appointed director

Kintara Therapeutics, Inc. (DMPI) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Quarterly results
10/04/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
09/26/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
06/30/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "FRANCISCO V. AGUILAR Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 684-5708 Website: www.nvsos.gov Profit Corporation: Certificate of Amendment Certificate to Accompany Restated Articles or Amended and Restated Articles Officer's Statement TYPE OR PRINT - USE DARK INK ONLY - DO NOT HIGHLIGHT 1. Entity information: Name of entity as on file with the Nevada Secretary of State: Kintara Therapeutics, Inc. Entity or Nevada Business Identification Number : NV20091193377 2. Restated or Amended and Restated Articles: Certificate to Accompany Restated Articles or Amended and Restated Articles Restated Articles - No amendments; articles are restated only and are signed by an officer of the corporation who has been authorized to execute the certificate by resolution of th..."
06/02/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/25/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2023 8-K Quarterly results
Docs: "SUMMARY OF FINANCIAL RESULTS FOR FISCAL YEAR 2023 THIRD QUARTER ENDED MARCH 31, 2023 As of March 31, 2023, Kintara had cash and cash equivalents of approximately $3.0 million. For the three months ended March 31, 2023, Kintara reported a net loss of approximately $3.3 million, or $1.94 per share, compared to a net loss of approximately $5.4 million, or $5.45 per share, for the three months ended March 31, 2022. For the nine months ended March 31, 2023, Kintara reported a net loss of approximately $11.3 million, or $7.32 per share, compared to a net loss of approximately $17.2 million, or $22.39 per share, for the nine months ended March 31, 2022. The decreased net losses for the three and nine months ended March 31, 2023 compared to the three and nine months ended March 31, 2022 was largel..."
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
03/31/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/31/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/31/2023 ARS Form ARS - Annual Report to Security Holders:
03/21/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
02/14/2023 8-K Quarterly results
Docs: "SUMMARY OF FINANCIAL RESULTS FOR FISCAL YEAR 2023 SECOND QUARTER ENDED DECEMBER 31, 2022 As of December 31, 2022, Kintara had cash and cash equivalents of approximately $4.9 million. For the three months ended December 31, 2022, Kintara reported a net loss of approximately $3.5 million, or $2.10 per share, compared to a net loss of approximately $5.9 million, or $6.07 per share, for the three months ended December 31, 2021. For the six months ended December 31, 2022, Kintara reported a net loss of approximately $8.1 million, or $5.42 per share, compared -1- to a net loss of approximately $11.9 million, or $17.30 per share, for the six months ended December 31, 2021. The decreased net losses for the three and six months ended December 31, 2022 compared to the three and six months ended Dece..."
02/14/2023 10-Q Quarterly Report for the period ended December 31, 2022
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/06/2023 4 Brown Dennis M (Chief Scientific Officer) has filed a Form 4 on Kintara Therapeutics, Inc.
Txns: Acquired (by will) 363 shares @ $0
12/05/2022 8-K Quarterly results
11/30/2022 8-K Quarterly results
11/14/2022 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 684-5708 Website: www.nvsos.gov Certificate of Change Pursuant to NRS 78.209 TYPE OR PRINT - USE DARK INK ONLY - DO NOT HIGHLIGHT INSTRUCTIONS: 1. Enter the current name as on file with the Nevada Secretary of State and enter the Entity or Nevada Business Identification Number . 2. Indicate the current number of authorized shares and par value, if any, and each class or series before the change. 3. Indicate the number of authorized shares and par value, if any of each class or series after the change. 4. Indicate the change of the affected class or series of issued, if any, shares after the change in exchange for each issued share of the same class or series. 5. Indicate provisions, if any, regard..."
11/09/2022 8-K Quarterly results
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/19/2022 8-K Quarterly results
09/27/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
09/27/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "SUMMARY OF FINANCIAL RESULTS FOR FISCAL YEAR ENDED JUNE 30, 2022 -1- At June 30, 2022, Kintara had cash and cash equivalents of approximately $11.8 million. During the year ended June 30, 2022, the Company completed two registered direct offerings for aggregate net proceeds to the Company of approximately $21.6 million. For the year ended June 30, 2022, Kintara reported a net loss of approximately $22.7 million, or $0.52 per share, compared to a net loss of approximately $38.3 million, or $1.60 per share, for the year ended June 30, 2021. The decreased net loss for the year ended June 30, 2022 compared to the year ended June 30, 2021 was largely due to the recognition of $16.1 million of non-cash expenses related to the acquisition of in-process research and development costs associated wi..."
09/27/2022 10-K Annual Report for the period ended June 30, 2022
08/03/2022 4 Praill Anthony Scott (CFO) has filed a Form 4 on Kintara Therapeutics, Inc.
Txns: Granted 240,087 shares @ $0
Granted 720,260 options to buy @ $0.1757, valued at $126.5k
08/03/2022 4 Brown Dennis M (Chief Scientific Officer) has filed a Form 4 on Kintara Therapeutics, Inc.
Txns: Granted 240,087 shares @ $0
Granted 720,260 options to buy @ $0.1757, valued at $126.5k
08/03/2022 4 Hoffman Robert E. (President and CEO) has filed a Form 4 on Kintara Therapeutics, Inc.
Txns: Granted 400,145 shares @ $0
Granted 1,200,634 options to buy @ $0.1757, valued at $211k
08/03/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "PURCHASE AGREEMENT PURCHASE AGREEMENT , dated as of August 2, 2022, by and between KINTARA THERAPEUTICS, INC., a Nevada corporation , LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company . WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to buy from the Company, up to Twenty Million Dollars of the Company's common stock, par value $0.001 per share . The shares of Common Stock to be purchased hereunder are referred to herein as the "Purchase Shares." NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby a...",
"REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT , dated as of August 2, 2022, by and between KINTARA THERAPEUTICS, INC., a Nevada corporation , and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company . Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof . WHEREAS: A. Upon the terms and subject to the conditions of the Purchase Agreement, the Company has agreed to issue to the Investor, and the Investor has agreed to purchase, up to Twenty Million Dollars of the Company's common stock, par value $0.001 per share , pursuant to the Purchase Agreement , and the Company has agreed to issue to the Investor 1,630,191 shares ...",
"Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital"
08/03/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/05/2022 4 Johnson Laura L. (Director) has filed a Form 4 on Kintara Therapeutics, Inc.
Txns: Granted 100,000 options to buy @ $0.255, valued at $25.5k
07/05/2022 4 TOTH ROBERT JOSEPH JR (Director) has filed a Form 4 on Kintara Therapeutics, Inc.
Txns: Granted 100,000 options to buy @ $0.255, valued at $25.5k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy